Evidence map›Paper›PMID 30970082›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2019

Diagnostic accuracy of thromboelastometry and its correlation with the HPLC-MS/MS quantification test.

V F de Aranda, P B M Derogis, L R Sanches, C L P Mangueira, M Katz, A C L Faulhaber, C E A Mendes, C E Dos Santos Ferreira, C N França, J C de Campos Guerra

Open access · goldAbstract read
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

V F de ArandaHospital Israelita Albert Einstein, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0002-3246-4358
P B M DerogisHospital Israelita Albert Einstein, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0003-2345-3996
L R SanchesHospital Israelita Albert Einstein, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0003-3697-5371
C L P MangueiraHospital Israelita Albert Einstein, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0002-4227-3723
M KatzHospital Israelita Albert Einstein, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0003-1909-6607
A C L FaulhaberHospital Israelita Albert Einstein, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0003-0998-1733
C E A MendesHospital Israelita Albert Einstein, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0002-2275-3981
C E Dos Santos FerreiraHospital Israelita Albert Einstein, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0001-9149-1252
C N FrançaPós Graduação em Ciências da Saúde, Universidade Santo Amaro, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0002-4167-4293
J C de Campos GuerraHospital Israelita Albert Einstein, São Paulo, SP, Brasil.ORCID http://orcid.org/0000-0002-4156-529X
Hospital Israelita Albert Einstein · BRUniversidade de Santo Amaro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to evaluate the diagnostic accuracy of thromboelastometry for assessing rivaroxaban concentrations. The accuracy of thromboelastometry was compared with the high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method, which is the gold standard for drug plasma monitoring (the reference standard). Forty-six clinically stable patients were treated with 10, 15, or 20 mg of rivaroxaban once daily (OD group) or 15 mg twice a day (BID group) (no particular indication for treatment). Patient samples were collected 2 h after the use of the medication (peak) and 2 h before the next dose (trough). The rivaroxaban plasma concentrations were determined via HPLC-MS/MS, and thromboelastometry was performed using a ROTEM® delta analyzer. There were significant prolongations in clotting time (CT) for the 10, 15, and 20 mg of rivaroxaban treatments in the OD groups. In the 15 mg BID group, the responses at the peak and trough times were similar. At the peak times, there was a positive correlation between the plasma concentration of rivaroxaban and CT (Spearman correlation rho=0.788, P<0.001) and clot formation time (rho=0.784, P<0.001), and a negative correlation for alpha angle (rho=-0.771, P<0.001), amplitude after 5 min (rho=-0.763, P<0.001), and amplitude after 10 min (rho=-0.680, P<0.001). The CT presented higher specificity and sensitivity using the cut-off determined by the receiver characteristics curve. ROTEM has potential as screening tool to measure possible bleeding risk associated with rivaroxaban plasma levels.

Indexed as

AdultAgedAged, 80 and overBlood Coagulation TestsChromatography, High Pressure LiquidData AccuracyDrug MonitoringFactor Xa InhibitorsFemaleHemorrhageHumansMaleMiddle AgedRivaroxabanTandem Mass SpectrometryThrombelastographyFactor Xa InhibitorsRivaroxaban

Identifiers

PMID30970082
PMCPMC6459466
OpenAlexW2930161801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.